Denmark rejects Janssen and Genmab drug twice in January
Danish drug regulator the Danish Medicines Council has decided not to recommend Darzalex in two different combination treatments, citing costs and uncertain effects.
by albert rønning-andersson, translated by daniel pedersen
During its monthly meeting in January, the Danish Medicines Council has rejected two applications from Janssen, which was seeking indication expansions for cancer drug Darzalex, which was developed in collaboration with Danish biotech firm Genmab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark recommends three drugs
For subscribers
CHMP recommends expanded approval of Dupixent
For subscribers
FDA approves ALK's house dust mite tablet for teens
For subscribers
.jpg&w=384&q=75)
